Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 25
1976 45
1977 57
1978 82
1979 127
1980 130
1981 172
1982 212
1983 220
1984 260
1985 230
1986 198
1987 208
1988 215
1989 211
1990 216
1991 178
1992 142
1993 158
1994 161
1995 147
1996 120
1997 140
1998 140
1999 157
2000 193
2001 162
2002 155
2003 215
2004 181
2005 213
2006 240
2007 243
2008 225
2009 242
2010 222
2011 224
2012 262
2013 261
2014 322
2015 281
2016 271
2017 238
2018 249
2019 264
2020 286
2021 258
2022 251
2023 26
Text availability
Article attribute
Article type
Publication date

Search Results

8,845 results
Results by year
Filters applied: . Clear all
Page 1
Metoprolol succinate combination in the treatment of hypertension.
Papadopoulos DP, Papademetriou V. Papadopoulos DP, et al. Angiology. 2009 Oct-Nov;60(5):608-13. doi: 10.1177/0003319708326450. Epub 2008 Nov 24. Angiology. 2009. PMID: 19033265 Review.
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used since 1975. ...A 100-mg metoprolol controlled/extended-release tablet contains 95 mg of metoprolol succinate and is considered to have equivalent activity of 100 mg metoprolol tar
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used since 1975. ...A 100-mg metoprolol controlled/extende
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
POISE Study Group; Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. POISE Study Group, et al. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12. Lancet. 2008. PMID: 18479744 Free article. Clinical Trial.
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0053). ...Patients are unlikely to accept the risks associated with perioperative extended-release metoprolol....
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0 …
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, Poulsen SH. Dybro AM, et al. J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024. J Am Coll Cardiol. 2022. PMID: 35450573 Clinical Trial.
CONCLUSIONS: In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree …
CONCLUSIONS: In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol
Metoprolol Improves Myocardial Remodeling and Cardiac Function in Patients with Permanent Pacemaker Implantation.
Ye L, Hu G, Yu H, Sun J, Yuan H. Ye L, et al. J Healthc Eng. 2022 Apr 11;2022:7340992. doi: 10.1155/2022/7340992. eCollection 2022. J Healthc Eng. 2022. PMID: 35449861 Free PMC article.

At one week after surgery, QTd, Pd, and Tp-Te are not significantly different (P > 0.05) between the metoprolol group and the control group, whereas the QTd and Pd times in the metoprolol group are lower than those in the control group (p < 0.05) at the 12-mon

At one week after surgery, QTd, Pd, and Tp-Te are not significantly different (P > 0.05) between the metoprolol group and the cont …
Drug therapy: metoprolol.
Koch-Weser J. Koch-Weser J. N Engl J Med. 1979 Sep 27;301(13):698-703. doi: 10.1056/NEJM197909273011306. N Engl J Med. 1979. PMID: 225665 Review. No abstract available.
Metoprolol: a review of its use in chronic heart failure.
Prakash A, Markham A. Prakash A, et al. Drugs. 2000 Sep;60(3):647-78. doi: 10.2165/00003495-200060030-00011. Drugs. 2000. PMID: 11030472 Review.
The incidence of sudden death and death due to progressive heart failure were both significantly decreased with metoprolol CR/XL. Similarly, a trend towards decreased mortality in the metoprolol CR/XL group compared with placebo was observed in the RESOLVD trial. .. …
The incidence of sudden death and death due to progressive heart failure were both significantly decreased with metoprolol CR/XL. Sim …
Metoprolol CR/XL in the treatment of chronic heart failure.
Gattis WA. Gattis WA. Pharmacotherapy. 2001 May;21(5):604-13. doi: 10.1592/phco.21.6.604.34551. Pharmacotherapy. 2001. PMID: 11349749 Review.
Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a beta1-selective agent that improved survival and reduced hospitalization among patients with New York Heart Association class II-IV heart failure in a randomized trial. Metoprolol CR/XL dif
Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a beta1-selective agent that improved survival and reduced
Metoprolol succinate extended release/hydrochlorothiazide combination tablets.
Hainer JW, Sugg J. Hainer JW, et al. Vasc Health Risk Manag. 2007;3(3):279-88. Vasc Health Risk Manag. 2007. PMID: 17703635 Free PMC article. Review.
Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient's BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize the value of combination antihypertensive regimens, not …
Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient's BP response, and low response rates …
Metoprolol (Lopressor).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1978 Nov 3;20(22):97-8. Med Lett Drugs Ther. 1978. PMID: 30035 Clinical Trial. No abstract available.
Metoprolol-controlled release, zero order kinetics.
Kendall MJ. Kendall MJ. J Clin Pharm Ther. 1989 Jun;14(3):159-79. doi: 10.1111/j.1365-2710.1989.tb00235.x. J Clin Pharm Ther. 1989. PMID: 2668307 Review.
Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used beta 1-selective, beta-adrenoceptor blocking drug, (beta 1-blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. ...
Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used beta 1-selective, beta-adreno
8,845 results